US5624893A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
Assignee: Alcon Research LLC
•
Filing: 1994-12-13
•
Granted: 1997-04-29
•
Expires: 2014-12-13
Abstract
Abstract Methods for treating the cornea following laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators and pain mediators to the eye. Compositions for use in treating the cornea are also disclosed.
Inventors
- 👤 John M. Yanni
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 12:34
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A61K31/00; A61K38/00; A61K38/04; A61K38/043; A61K38/046; A61K38/08; A61K38/16; A61K38/55; A61K38/56
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
87 words
A method for treating the cornea for haze or pain following laser irradiation and resulting photoablation of corneal tissue comprising, applying to the affected eye, a therapeutically effective amount of a composition comprising a wound healing modulator and a pain mediator wherein the wound healing modulator is selected from the group consisting of: steroids, growth factors, basement membrane components, anti-oxidants, regulators of collagen structure, aldose reductase inhibitors, nonsteroidal antiiflammatories, immunomodulators, antiallergics, fatty acid derivatives of arachidonic acid and antimicrobials and the pain mediator is a neurokinin-1 antagonist.
Claim 2
Independent Claim
87 words
A method for treating the cornea for haze or pain following laser irradiation and resulting photoablation of corneal tissue comprising, applying to the affected eye, a therapeutically effective amount of a composition comprising a wound healing modulator and a pain mediator wherein the wound healing modulator is selected from the group consisting of: steroids, growth factors, basement membrane components, anti-oxidants, regulators of collagen structure, aldose reductase inhibitors, nonsteroidal antiiflammatories, immunomodulators, antiallergics, fatty acid derivatives of arachidonic acid and antimicrobials and the pain mediator is a neurokinin-1 antagonist.
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein the wound healing modulator comprises asteroid.
Claim 4
Dependent Claim
21 words
The method of claim 2 wherein the steroid is present at a concentration between about 0.1 and about 4.0 wt. %.
Claim 5
Dependent Claim
18 words
The method of claim 3 wherein the steroid comprises dexamethasone or a pharmaceutically acceptable salt or ester thereof.
Claim 6
Dependent Claim
18 words
The method of claim 3 wherein the steroid comprises prednisone or a pharmaceutically acceptable salt or ester thereof.
Claim 7
Dependent Claim
18 words
The method of claim 3 wherein the steroid comprises fluorometholone or a pharmaceutically acceptable salt or ester thereof.
Claim 8
Dependent Claim
18 words
The method of claim 3 wherein the steroid comprises Rimexolone or a pharmaceutically acceptable salt or ester thereof.
Claim 9
Dependent Claim
90 words
A topical ophthalmic composition for treating the cornea for haze or pain following photoablation of the corneal during ophthalmic surgery, comprising, a therapeutically effective amount of a wound healing modulator, a therapeutically effective amount of a pain mediator and an ophthalmically acceptable carrier therefore, wherein the wound healing modulator is selected from the group consisting of: steroids, growth factors, basement membrane components, anti-oxidants, regulators of collagen structure, aldose reductase inhibitors, nonsteroidal antiiflammatories, immunomodulators, antiallergics, fatty acid derivatives of arachidonic acid and antimicrobials and the pain mediator is a neurokinin-1 antagonist.
Claim 10
Dependent Claim
90 words
A topical ophthalmic composition for treating the cornea for haze or pain following photoablation of the corneal during ophthalmic surgery, comprising, a therapeutically effective amount of a wound healing modulator, a therapeutically effective amount of a pain mediator and an ophthalmically acceptable carrier therefore, wherein the wound healing modulator is selected from the group consisting of: steroids, growth factors, basement membrane components, anti-oxidants, regulators of collagen structure, aldose reductase inhibitors, nonsteroidal antiiflammatories, immunomodulators, antiallergics, fatty acid derivatives of arachidonic acid and antimicrobials and the pain mediator is a neurokinin-1 antagonist.
Claim 11
Dependent Claim
12 words
The composition of claim 8 wherein the wound healing modulator comprises asteroid.
Claim 12
Dependent Claim
22 words
The composition of claim 9 wherein the steroid is present at a concentration of between about 0.1 and about 4.0 wt. %.
Claim 13
Dependent Claim
18 words
The composition of claim 10 wherein the steroid comprises dexamethasone or a pharmaceutically acceptable salt or ester thereof.
Claim 14
Dependent Claim
18 words
The composition of claim 10 wherein the steroid comprises prednisone or a pharmaceutically acceptable salt or ester thereof.
Claim 15
Dependent Claim
18 words
The composition of claim 10 wherein the steroid comprises fluorometholone or a pharmaceutically acceptable salt or ester thereof.
Claim 16
Dependent Claim
18 words
The composition of claim 10 wherein the steroid comprises Rimexolone or a pharmaceutically acceptable salt or ester thereof.
Claim 17
Independent Claim
29 words
A method for treating the cornea following laser irradiation and resulting photoablation of corneal tissue comprising, applying to the affected eye, a therapeutically effective amount of a neurokinin-1 antagonist.
Claim 18
Independent Claim
29 words
A method for treating the cornea following laser irradiation and resulting photoablation of corneal tissue comprising, applying to the affected eye, a therapeutically effective amount of a neurokinin-1 antagonist.
References Cited (Backward Citations)
US3714140A
Cited
US3947478A
Cited
US4454151A
Cited
US4436745A
Cited
US4438272A
Cited
US4599353A
Cited
US4559343A
Cited
US4474751A
Cited
GB2144993A
Cited
EP0140998A1
Cited
US4665913A
Cited
US4732148A
Cited
US4600717A
Cited
US4717725A
Cited
US4717727A
Cited
WO1986002271A1
Cited
US4966911A
Cited
EP0189272A2
Cited
EP0190018A2
Cited
US4797422A
Cited
US4686214A
Cited
US4983580A
Cited
US4692460A
Cited
US5036056A
Cited
US4923963A
Cited
US5124392A
Cited
US5242902A
Cited
US5098896A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-04-28 | 2000-10-28 | 2001-04-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-04-28 | 2004-10-28 | 2005-04-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-04-28 | 2008-10-28 | 2009-04-29 | $7700.00 | Window Closed / Lapsed |